tiprankstipranks
Trending News
More News >
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
US Market
Advertisement

Arvinas Holding Company (ARVN) Earnings Dates, Call Summary & Reports

Compare
1,034 Followers

Earnings Data

Report Date
Mar 02, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.53
Last Year’s EPS
-0.63
Same Quarter Last Year
Moderate Buy
Based on 16 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 05, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call revealed significant progress in Arvinas' clinical pipeline, particularly with ARV-102 and financial stability, but was tempered by a notable revenue decline and ongoing challenges in achieving efficacious exposure levels in some trials.
Company Guidance
During Arvinas' Third Quarter 2025 Earnings Call, the company provided guidance on its ongoing and future clinical and financial strategies. The company reported $787.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and announced a share repurchase program of up to $100 million, highlighting confidence in its long-term strategy. Arvinas is advancing multiple clinical programs, including the ARV-102, ARV-393, and ARV-806, with promising early-stage data in oncology and neurology. The LRRK2 degrader, ARV-102, is shown to be well-tolerated with significant reductions in LRRK2 protein in clinical trials, while the BCL6 degrader, ARV-393, has demonstrated early responses in lymphomas. Additionally, Arvinas is preparing for a Phase Ib trial for ARV-102 in PSP and anticipates further preclinical data releases, including from the HPK1 degrader, ARV-6723. These developments, alongside strategic collaborations, are expected to drive shareholder value with an operational cash runway extending into the second half of 2028.
Strong Pipeline Progress
Arvinas entered a data-rich period with multiple early-stage clinical readouts, including ARV-102, ARV-806, and ARV-027, along with promising preclinical data from ARV-393 and ARV-6723.
Promising ARV-102 Data
ARV-102 showed up to 90% LRRK2 reduction in healthy volunteers and 97% reduction in Parkinson's patients, indicating strong potential for treating neurodegenerative diseases.
Financial Stability
Arvinas reported cash, cash equivalents, and marketable securities of $787.6 million, providing financial and strategic flexibility into the second half of 2028.
Strategic Collaboration with Pfizer
Arvinas and Pfizer jointly selected a third party for the commercialization of vepdegestrant, with the goal of launching it if approved.

Arvinas Holding Company (ARVN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ARVN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 02, 2026
2025 (Q4)
-0.53 / -
-0.63
Nov 05, 2025
2025 (Q3)
-0.70 / -0.48
-0.6829.41% (+0.20)
Aug 06, 2025
2025 (Q2)
-0.93 / -0.84
-0.49-71.43% (-0.35)
May 01, 2025
2025 (Q1)
-0.96 / 1.14
-0.97217.53% (+2.11)
Feb 11, 2025
2024 (Q4)
-0.95 / -0.63
-2.5375.10% (+1.90)
Oct 30, 2024
2024 (Q3)
-0.84 / -0.68
-1.1842.37% (+0.50)
Jul 30, 2024
2024 (Q2)
-1.08 / -0.49
-1.2560.80% (+0.76)
May 07, 2024
2024 (Q1)
-1.42 / -0.97
-1.5437.01% (+0.57)
Feb 27, 2024
2023 (Q4)
-1.19 / -2.53
-1.56-62.18% (-0.97)
Nov 07, 2023
2023 (Q3)
-1.58 / -1.18
-1.244.84% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ARVN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 05, 2025
$9.54$9.57+0.31%
Aug 06, 2025
$7.61$6.43-15.51%
May 01, 2025
$9.62$7.23-24.84%
Feb 11, 2025
$18.97$17.68-6.80%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Arvinas Holding Company (ARVN) report earnings?
Arvinas Holding Company (ARVN) is schdueled to report earning on Mar 02, 2026, TBA (Confirmed).
    What is Arvinas Holding Company (ARVN) earnings time?
    Arvinas Holding Company (ARVN) earnings time is at Mar 02, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ARVN EPS forecast?
          ARVN EPS forecast for the fiscal quarter 2025 (Q4) is -0.53.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis